Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amitifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 15/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 15/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitifadine SCHEMBL79279 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL30231901 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL378242 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855350 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855353 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL378061 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL8213058 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL12313135 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL29393526 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL4552778 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349835-B1 | (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE, COMPOSITIONS AND USES THEREOF | EUTHYMICS BIOSCIENCE INC (US) | 2016-03-30 | — | — | EP | claimed |
| US-20120010260-A1 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | ABOU-GHARBIA MAGID A (US) | 2012-01-12 | — | — | US | claimed |
| US-20110294847-A1 | Novel Polymorphs Of Azabicyclohexane | ETHISMOS RESEARCH, INC. | 2011-12-01 | — | — | US | claimed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | claimed |
| WO-2008013856-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL -3-AZABICYCLO[3.1.0 ] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| EP-1773320-A1 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | Wyeth (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060173064-A1 | (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders | LIPPA ARNOLD S | 2006-08-03 | — | — | US | claimed |
| WO-2006012474-A1 | METHOD FOR TREATING NERVOUS SYSTEM DISORDERS AND CONDITIONS | WYETH (US) | 2006-02-02 | — | — | WO | claimed |
| US-20060020015-A1 | Method for treating nervous system disorders and conditions | WYETH (US) | 2006-01-26 | — | — | US | claimed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | claimed |
| EP-4687890-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| WO-2024211911-A1 | METHODS FOR TREATING DEPRESSIVE STATES | OAKTREE FUND ADMINISTRATION, LLC (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4395772-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | Ethismos Research, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4088652-A | Acylazabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | SLC6A2 3023/4885SLC6A4 2230/4885SLC6A3 982/4885 |
| US-20110294847-A1 | Novel Polymorphs Of Azabicyclohexane | CYP3A43, CYP2D6, CYP26B1 | SLC6A2 2523/4885SLC6A4 1901/4885SLC6A3 1079/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | SLC6A2 138/4885SLC6A4 397/4885SLC6A3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.